Clinical Trial: Carfilzomb, Lenalidomide and Dex for Smoldering Myeloma

More treatment options are being considered for high risk smoldering multiple myeloma patients who are likely to progress to active myeloma.  The current standard of care for smoldering myeloma is close follow-up without treatment until multiple myeloma develops. However, researchers are studying possible treatments for smoldering myeloma itself. One possible treatment involves a combination of cancer treatment drugs.

This study is open at the NIH in Maryland and uses a triple combination also used in multiple myeloma. Lenalidomide is a drug that may help reduce or prevent the growth of cancer cells. Dexamethasone is a steroid that is often given with other anti-cancer drugs. These two drugs are an approved treatment for multiple myeloma that has not responded to at least one other treatment. Carfilzomib is an experimental drug that has been effective in treating multiple myeloma. Researchers want to combine these three drugs to see if they are a safe and effective treatment for SMM.

Learn more about this study on SparkCures:

Smoldering Myeloma Clinical Trial